{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:22:31Z","timestamp":1781770951227,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Fremanezumab, a fully humanized monoclonal antibody (mAb; IgG2\u0394a) that selectively targets calcitonin gene-related peptide (CGRP), is approved for the preventive treatment of migraine in adults. The efficacy and safety of fremanezumab for migraine prevention have been demonstrated in randomized, double-blind, placebo-controlled trials. Real-world effectiveness data are needed to complement clinical trial data. This study assessed the effectiveness of fremanezumab across different subgroups of adult patients with episodic migraine (EM), chronic migraine (CM), or difficult-to-treat (DTT) migraine in real-world clinical settings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective, panel-based online chart review used electronic case report forms. Patient inclusion criteria were a physician diagnosis of EM or CM; age\u2009\u2265\u200918\u2009years at the time of first fremanezumab initiation; \u2265\u20091 dose of fremanezumab treatment; \u2265\u20091 follow-up visit since first initiation; and\u2009\u2265\u20092 measurements of monthly migraine days (MMD; with 1 within a month before or at first initiation and\u2009\u2265\u20091 after first initiation). Changes in MMD and monthly headache days were assessed during the follow-up period. These endpoints were evaluated in subgroups of patients by migraine type (EM\/CM) and in subgroups with DTT migraine (diagnosis of medication overuse [MO], major depressive disorder [MDD], generalized anxiety disorder [GAD], or prior exposure to a different CGRP pathway\u2013targeted mAb [CGRP mAb]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data were collected from 421 clinicians and 1003 patients. Mean (percent) reductions from baseline in MMD at Month 6 were\u2009\u2212\u20097.7 (77.0%) in EM patients, \u2212\u200910.1 (68.7%) in CM patients, \u2212\u200910.8 (80.6%) in the MO subgroup, \u2212\u20099.9 (68.3%) in the MDD subgroup, \u2212\u20099.5 (66.4%) in the GAD subgroup, and\u2009\u2212\u20099.0 (68.7%) in the prior CGRP mAb exposure subgroup. Improvements in MDD or GAD severity were reported by 45.5% and 45.8% of patients with comorbid MDD or GAD, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this real-world study, fremanezumab demonstrated effectiveness for migraine regardless of migraine type or the presence of factors contributing to DTT migraine (MO, GAD, MDD, or prior exposure to a different CGRP mAb).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01415-x","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T07:12:50Z","timestamp":1652685170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine"],"prefix":"10.1186","volume":"23","author":[{"given":"Maurice T.","family":"Driessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Patterson-Lomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Seminerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todor I.","family":"Totev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Ayyagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"issue":"4","key":"1415_CR1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/head.13281","volume":"58","author":"R Burch","year":"2018","unstructured":"Burch R, Rizzoli P, Loder E (2018) The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache 58(4):496\u2013505. https:\/\/doi.org\/10.1111\/head.13281","journal-title":"Headache"},{"key":"1415_CR2","doi-asserted-by":"publisher","unstructured":"GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396(10258):1204\u20131222. https:\/\/doi.org\/10.1016\/S0140-6736(20)30925-9","DOI":"10.1016\/S0140-6736(20)30925-9"},{"issue":"1","key":"1415_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s10194-018-0846-2","volume":"19","author":"TJ Steiner","year":"2018","unstructured":"Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z (2018) Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 19(1):17. https:\/\/doi.org\/10.1186\/s10194-018-0846-2","journal-title":"J Headache Pain"},{"issue":"1","key":"1415_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s10194-018-0907-6","volume":"19","author":"P Vo","year":"2018","unstructured":"Vo P, Fang J, Bilitou A, Laflamme AK, Gupta S (2018) Patients' perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain 19(1):82. https:\/\/doi.org\/10.1186\/s10194-018-0907-6","journal-title":"J Headache Pain"},{"issue":"1","key":"1415_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s41687-020-00221-w","volume":"4","author":"JH Ford","year":"2020","unstructured":"Ford JH, Foster SA, Nichols RM, Tockhorn-Heidenreich A, Ye W, Jackson J et al (2020) A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe. J Patient Rep Outcomes 4(1):53. https:\/\/doi.org\/10.1186\/s41687-020-00221-w","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"1415_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jval.2012.08.2212","volume":"16","author":"D Serrano","year":"2013","unstructured":"Serrano D, Manack AN, Reed ML, Buse DC, Varon SF, Lipton RB (2013) Cost and predictors of lost productive time in chronic migraine and episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Value Health 16(1):31\u201338. https:\/\/doi.org\/10.1016\/j.jval.2012.08.2212","journal-title":"Value Health"},{"issue":"6","key":"1415_CR7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.15252\/embr.201642519","volume":"17","author":"P Hunter","year":"2016","unstructured":"Hunter P (2016) New migraine therapies promise prevention: a new generation of drugs could avert migraine attacks rather than merely relieve symptoms. EMBO Rep 17(6):797\u2013799. https:\/\/doi.org\/10.15252\/embr.201642519","journal-title":"EMBO Rep"},{"issue":"8","key":"1415_CR8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10194-012-0479-9","volume":"13","author":"S Ashina","year":"2012","unstructured":"Ashina S, Serrano D, Lipton RB, Maizels M, Manack AN, Turkel CC et al (2012) Depression and risk of transformation of episodic to chronic migraine. J Headache Pain 13(8):615\u2013624. https:\/\/doi.org\/10.1007\/s10194-012-0479-9","journal-title":"J Headache Pain"},{"key":"1415_CR9","doi-asserted-by":"publisher","unstructured":"Schwedt TJ, Alam A, Reed ML, Fanning KM, Munjal S, Buse DC et al (2018) Factors associated with acute medication overuse in people with migraine: results from the 2017 Migraine in America Symptoms and Treatment (MAST) study. J Headache Pain 19(1):38. https:\/\/doi.org\/10.1186\/s10194-018-0865-z","DOI":"10.1186\/s10194-018-0865-z"},{"issue":"8","key":"1415_CR10","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","volume":"48","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB (2008) Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 48(8):1157\u20131168. https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01217.x","journal-title":"Headache"},{"key":"1415_CR11","doi-asserted-by":"publisher","unstructured":"Lipton RB, Iyer R, Cohen J, Jackson J, Ramirez-Campos V, Cotton S et al (2019) Burden of comorbid depression and anxiety on migraine-specific health-related quality of life in adult migraine patients in the United States. Value Health 22(Suppl 3):S756. https:\/\/doi.org\/10.1016\/j.jval.2019.09.1872","DOI":"10.1016\/j.jval.2019.09.1872"},{"key":"1415_CR12","doi-asserted-by":"publisher","unstructured":"Lipton RB, Seng EK, Chu MK, Reed ML, Fanning KM, Adams AM et al (2020) The effect of psychiatric comorbidities on headache-related disability in migraine: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache 60(8):1683\u20131696. https:\/\/doi.org\/10.1111\/head.13914","DOI":"10.1111\/head.13914"},{"issue":"3","key":"1415_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1212\/cpj.0000000000001076","volume":"11","author":"L Newman","year":"2021","unstructured":"Newman L, Vo P, Zhou L, Lopez Lopez C, Cheadle A, Olson M et al (2021) Health care utilization and costs in patients with migraine who have failed previous preventive treatments. Neurol Clin Pract 11(3):206\u2013215. https:\/\/doi.org\/10.1212\/cpj.0000000000001076","journal-title":"Neurol Clin Pract"},{"key":"1415_CR14","unstructured":"AJOVY (2020) AJOVY (fremanezumab-vfrm) [prescribing information]. North Wales (PA): Teva Pharmaceuticals USA, Inc. Revised 2020. Available from: https:\/\/www.ajovyhcp.com\/globalassets\/ajovy\/ajovy-pi.pdf"},{"issue":"22","key":"1415_CR15","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa1709038","journal-title":"N Engl J Med"},{"issue":"19","key":"1415_CR16","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999\u20132008. https:\/\/doi.org\/10.1001\/jama.2018.4853","journal-title":"JAMA"},{"issue":"10203","key":"1415_CR17","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/s0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394(10203):1030\u20131040. https:\/\/doi.org\/10.1016\/s0140-6736(19)31946-4","journal-title":"Lancet"},{"issue":"1","key":"1415_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-020-01173-8","volume":"21","author":"SD Silberstein","year":"2020","unstructured":"Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z (2020) The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 21(1):114. https:\/\/doi.org\/10.1186\/s10194-020-01173-8","journal-title":"J Headache Pain"},{"issue":"4","key":"1415_CR19","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/head.14097","volume":"61","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Cohen JM, Galic M, Seminerio MJ, Yeung PP, Aycardi E et al (2021) Effects of fremanezumab in patients with chronic migraine and comorbid depression: subgroup analysis of the randomized HALO CM study. Headache 61(4):662\u2013672. https:\/\/doi.org\/10.1111\/head.14097","journal-title":"Headache"},{"key":"1415_CR20","doi-asserted-by":"publisher","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R et al (2020) Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology 95(18):e2487\u2013e2499. https:\/\/doi.org\/10.1212\/WNL.0000000000010600","DOI":"10.1212\/WNL.0000000000010600"},{"issue":"1","key":"1415_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-021-01279-7","volume":"22","author":"M Ashina","year":"2021","unstructured":"Ashina M, Cohen JM, Galic M, Campos VR, Barash S, Ning X et al (2021) Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. J Headache Pain 22(1):68. https:\/\/doi.org\/10.1186\/s10194-021-01279-7","journal-title":"J Headache Pain"},{"key":"1415_CR22","doi-asserted-by":"publisher","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21(1):32. https:\/\/doi.org\/10.1186\/s10194-020-01102-9","DOI":"10.1186\/s10194-020-01102-9"},{"issue":"10","key":"1415_CR23","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/0333102418788347","volume":"38","author":"M Ashina","year":"2018","unstructured":"Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D et al (2018) Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 38(10):1611\u20131621. https:\/\/doi.org\/10.1177\/0333102418788347","journal-title":"Cephalalgia"},{"issue":"9","key":"1415_CR24","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ (2020) Real-world patient experience with erenumab for the preventive treatment of migraine. Headache 60(9):2014\u20132025. https:\/\/doi.org\/10.1111\/head.13951","journal-title":"Headache"},{"issue":"6","key":"1415_CR25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0333102420912726","volume":"40","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein SD et al (2020) Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia 40(6):543\u2013553. https:\/\/doi.org\/10.1177\/0333102420912726","journal-title":"Cephalalgia"},{"key":"1415_CR26","doi-asserted-by":"publisher","unstructured":"Torres-Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (2021) The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol. https:\/\/doi.org\/10.1007\/s00415-021-10523-8","DOI":"10.1007\/s00415-021-10523-8"},{"issue":"Suppl 2","key":"1415_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10072-020-04669-y","volume":"41","author":"F Vernieri","year":"2020","unstructured":"Vernieri F, Altamura C, Aurilia C, Brunelli N, Egeo G, Fofi L et al (2020) Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study). Neurol Sci 41(Suppl 2):487\u2013488. https:\/\/doi.org\/10.1007\/s10072-020-04669-y","journal-title":"Neurol Sci"},{"key":"1415_CR28","doi-asserted-by":"publisher","unstructured":"Faust E, Pivneva I, Yang K, Betts KA, Ahmed Z, Joshi S et al (2021) Real-world treatment profiles, clinical outcomes, and healthcare resource utilization of patients with migraine prescribed erenumab: a multicenter chart-review study of US headache centers. Neurol Ther. https:\/\/doi.org\/10.1007\/s40120-021-00245-4","DOI":"10.1007\/s40120-021-00245-4"},{"issue":"4","key":"1415_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000612","volume":"2","author":"KB Alstadhaug","year":"2017","unstructured":"Alstadhaug KB, Ofte HK, Kristoffersen ES (2017) Preventing and treating medication overuse headache. Pain Rep 2(4):e612. https:\/\/doi.org\/10.1097\/PR9.0000000000000612","journal-title":"Pain Rep"},{"key":"1415_CR30","unstructured":"Lipton R, Cohen J, Yeung PP, Yang R, Ning X, Buse D (2019) Long-term efficacy of fremanezumab in patients with chronic migraine and comorbid moderate to severe depression (P1.10-024). Neurology 92(Supp 15):P1.10\u2013024"},{"issue":"8","key":"1415_CR31","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1212\/01.wnl.0000058907.41080.54","volume":"60","author":"N Breslau","year":"2003","unstructured":"Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM (2003) Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology 60(8):1308\u20131312. https:\/\/doi.org\/10.1212\/01.wnl.0000058907.41080.54","journal-title":"Neurology"},{"issue":"1","key":"1415_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/head.12004","volume":"53","author":"TA Smitherman","year":"2013","unstructured":"Smitherman TA, Kolivas ED, Bailey JR (2013) Panic disorder and migraine: comorbidity, mechanisms, and clinical implications. Headache 53(1):23\u201345. https:\/\/doi.org\/10.1111\/head.12004","journal-title":"Headache"},{"issue":"8","key":"1415_CR33","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1007\/s00415-012-6725-x","volume":"260","author":"DC Buse","year":"2013","unstructured":"Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB (2013) Psychiatric comorbidities of episodic and chronic migraine. J Neurol 260(8):1960\u20131969. https:\/\/doi.org\/10.1007\/s00415-012-6725-x","journal-title":"J Neurol"},{"issue":"2","key":"1415_CR34","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/head.13729","volume":"60","author":"C Ziegeler","year":"2020","unstructured":"Ziegeler C, May A (2020) Non-responders to treatment with antibodies to the CGRP-receptor may profit from a switch of antibody class. Headache 60(2):469\u2013470. https:\/\/doi.org\/10.1111\/head.13729","journal-title":"Headache"},{"issue":"8","key":"1415_CR35","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.nrleng.2020.10.008","volume":"36","author":"J Porta-Etessam","year":"2021","unstructured":"Porta-Etessam J, Gonz\u00e1lez-Garc\u00eda N, Guerrero \u00c1L, Garc\u00eda-Azor\u00edn D (2021) Failure of monoclonal antibodies against CGRP or its receptor does not imply lack of efficacy of other drugs from the same class. Neurologia (Engl Ed) 36(8):638\u2013640. https:\/\/doi.org\/10.1016\/j.nrleng.2020.10.008","journal-title":"Neurologia (Engl Ed)"},{"key":"1415_CR36","doi-asserted-by":"publisher","first-page":"333102421104876","DOI":"10.1177\/03331024211048765","volume":"13","author":"LH Overeem","year":"2021","unstructured":"Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A et al (2021) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia 13:3331024211048765. https:\/\/doi.org\/10.1177\/03331024211048765","journal-title":"Cephalalgia"},{"issue":"1","key":"1415_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61. https:\/\/doi.org\/10.1186\/s10194-020-01127-0","journal-title":"J Headache Pain"},{"issue":"13","key":"1415_CR38","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/0333102420946725","volume":"40","author":"S Kanaan","year":"2020","unstructured":"Kanaan S, Hettie G, Loder E, Burch R (2020) Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia 40(13):1511\u20131522. https:\/\/doi.org\/10.1177\/0333102420946725","journal-title":"Cephalalgia"},{"issue":"10","key":"1415_CR39","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1111\/head.13956","volume":"60","author":"A Alex","year":"2020","unstructured":"Alex A, Vaughn C, Rayhill M (2020) Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study. Headache 60(10):2454\u20132462. https:\/\/doi.org\/10.1111\/head.13956","journal-title":"Headache"},{"issue":"9","key":"1415_CR40","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.14194","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R et al (2021) Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study. Headache 61(9):1351\u20131363. https:\/\/doi.org\/10.1111\/head.14194","journal-title":"Headache"},{"key":"1415_CR41","doi-asserted-by":"publisher","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B et al (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: erenumab in real life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache 61(2):363\u2013372. https:\/\/doi.org\/10.1111\/head.14032","DOI":"10.1111\/head.14032"},{"issue":"1","key":"1415_CR42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G et al (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22(1):35. https:\/\/doi.org\/10.1186\/s10194-021-01247-1","journal-title":"J Headache Pain"},{"key":"1415_CR43","doi-asserted-by":"publisher","unstructured":"Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G et al (2022) Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol 29(4):1198\u20131208. https:\/\/doi.org\/10.1111\/ene.15197","DOI":"10.1111\/ene.15197"},{"key":"1415_CR44","doi-asserted-by":"publisher","unstructured":"Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L et al (2021) Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: a retrospective chart review. Pain Ther 10(2):809\u2013826. https:\/\/doi.org\/10.1007\/s40122-021-00264-x","DOI":"10.1007\/s40122-021-00264-x"},{"issue":"1","key":"1415_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15360288.2020.1829249","volume":"35","author":"M Armanious","year":"2021","unstructured":"Armanious M, Khalil N, Lu Y, Jimenez-Sanders R (2021) Erenumab and onabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis. J Pain Palliat Care Pharmacother 35(1):1\u20136. https:\/\/doi.org\/10.1080\/15360288.2020.1829249","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"1415_CR46","unstructured":"Goadsby PJ, Dodick DW, Silberstein SD, Yeung PP, Blankenbiller T, Ning X et al (2018) Efficacy of fremanezumab in patients with chronic migraine with or without concomitant use of preventive medications (P4.099). Neurology 90(15 Suppl):P4.099"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01415-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01415-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01415-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T07:12:56Z","timestamp":1652685176000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01415-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1415"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01415-x","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"6 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.T.D., S.F.T., M.J.S., and K.C. are employees of Teva Pharmaceuticals. J.M.C. is a former employee of Teva Pharmaceuticals. O.P-L., T.I.T., R.S., E.Y., F.M., and R.A. are employees of Analysis Group, which performed these analyses funded by Teva Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}